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This section entitled "Beta-blockers and heart failure" brings a review of particular interest today. The concept of using beta-blockers in the treatment of heart failure has emerged over the last 25 years. It started in the early seventies in Goteborg, Sweden. Hjalmarson and co-workers were involved in studying the importance of treating myocardial ischemia with beta-blockers. This work translated into heart failure associated with tachycardia. Initial observations were reported in 1975 [1] and were then followed by further documentation [2, 3] . In the mid nineties, more than 3000 patients had participated in placebo-controlled, randomised trials where, in a metaanalysis by Doughty et al. [4] , beta-blockers were significantly beneficial to patients with heart failure. It is therefore important to put various aspects of this topic together. In this issue reviews on etiology, remodelling, exercise, morbidity and mortality are presented. This reviews were prepared prior to the presentation of data from the cardiac insufficiency bisoprolol study II (CIBIS II) and MERrr. However, these two trials have contributed to making beta-blockers the best documented treatment for heart failure (Table 1 ).
In CIBIS II 2647 patients with chronic heart failure were chosen at random to take placebo or bisoprolol [5] . Baseline therapy included diuretics and an angiotensinconverting enzyme (ACE) inhibitor if tolerated. The study was stopped by the safety committee because of pronounced beneficial effects of bisoprolol. A 34% reduction in mortality was demonstrated after a mean follow-up of 1.3 years. Both sudden death and hospitalisations for heart failure were significantly reduced.
In MERIT 3991 patients in New York Heart Association (NYHA) class II-IV were randomly assigned placebo or metoprolol [6] . Treatment at baseline included an ACEinhibitor or an angiotensin-receptor antagonists in 96% of included patients. This study was also stopped by the safety committee. There was also a 34% highly significant decrease in mortality by metoprolol. The study was presented at the American College of Cardiologists (ACC) meeting in March 1999 and limited study results were available. The effects. were consistent across the predefined subgroups. Reduction in cardiovascular deaths was -38% and sudden deaths decreased by 41%.
Thus 9779 patients have been randomised in placebo controlled completed trials in heart failure. This makes beta-blockers the best documented and most effective treatment in this syndrome. What is presented in these reviews has been even more strengthened by these additional studies.
In a review on influence of etiology on the effects of treatment in heart failure Cleland and Swedberg point out the potential importance of different etiologies to heart failure. In patients with coronary artery disease, beneficial treatment effects could be due to protective effects on coronary arteries as well as on the myocardium itself. To sort out these possibilities, studies more closely focused on these options are needed.
The possibilities that left ventricular remodelling is influenced has been approached by Err! and Bu. They conclude that beta-blockers have a beneficial influence remodelling in chronic heart failure. They find the data post myocardial infarction to be more sparse and better documentation is needed.
Fowler has reviewed the studies evaluating morbidity and mortality before the results from CIBIS II and MERIT were available. He states "there are convincing data indicating that beta adrenergic blocking drugs exert a favourable influence on number of major morbid events among patients with heart failure".
Finally, the effects of beta-blockers on symptoms and exercise tolerance have been approached by Doughty and Sharpe. They conclude that "effects of beta-blockers and symptoms and exercise tolerance in patients with heart failure are inconsistent". However, studies have been performed primarily in patients with mild to moderate symptoms where there is a difficulty in obtaining positive results. Further trials are needed to clarify the role of betablockers in this context in patients with more severe heart failure.
In summary, this review in depth will provide an important review on a treatment that has now become a cornerstone in the management of patients with heart failure.
